Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Introduces Reusable Courier Transit Case

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
BioCarrier™ - Designed for local courier routes and multiple site sample collections.

Intelsius has introduced the first of its kind range of solutions, BioCarrier™, specifically designed for local courier routes and multiple site sample collections.

“Intelsius is proudly introducing the BioCarrier line to the life science leaders and industry professionals at the largest and most well attended clinical trial conference of the year,” said David Walsh, CEO, Intelsius. “This is a regulatory compliant solution rather than couriers carrying samples or medicines from clinic to clinic or pharmacy to pharmacy in picnic coolers.”

BioCarrier cases are designed to provide regular route, multiple site sample collection and “home visit” temperature-sensitive injectable drug protection.

The rugged polymer outer with the expanded polypropylene (EPP) insulated liner maintains payload integrity at 2-8 degrees Celsius for 12 hours plus or when using dry ice up to 18 hours.

All three sizes are regulatory compliant with pre-printed UN3373 labels for the shipment of Category B biological samples.

“The rigid, durable, regulatory compliant marked outer cases feature a clasp closure allowing the lid to be secured and the cases to be stacked and locked together, making them an Intelsius exclusive,” said Alex Roskoss, Intelsius European head of technical services.

“These cases were ergonomically designed specifically for couriers to enable safe, comfortable, compliant transportation around the corner or across town,” Roskoss added. Its discreet design keeps the contents confidential.

“Keeping people safe while samples or medicines are being transported around town is the primary reason for creating the BioCarrier line of products,” said Walsh.

Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!